Horiguchi Jun, Koibuchi Yukio, Iijima Kotaro, Yoshida Takashi, Yoshida Miho, Takata Daisuke, Oyama Tetsunari, Iino Yuichi, Morishita Yasuo
Second Department of Surgery, Gunma University Faculty of Medicine, Showa-machi 3-39-15, Maebashi, Gunma 371-8511, Japan.
Int J Mol Med. 2003 Dec;12(6):855-9.
Immunohistochemical double staining with estrogen receptor (ER) and epidermal growth factor receptor 2 (HER2) was conducted in tissue sample of 125 women with invasive breast cancer. The age at the time of surgery ranged from 28 to 82 years. The tumor size was 2 cm or less in 42 patients and larger than 2 cm in 83. Axillary lymph node status was positive in 53 patients and negative in 72. Estrogen receptor (ER) which was measured using enzyme immunoassay (EIA) was positive in 67 patients, negative in 50 and unknown in 8. Of the 125 patients evaluated, 83 (66.4%) were immunohistochemically positive for ER. ER by immunohistochemistry (IHC) (ER-IHC) was significantly (p<0.01) correlated with ER by EIA (ER-EIA). ER-EIA values in ER-IHC scores were 1.4 fmol/mg protein in score 0, 0.0 in score 1, 19.0 in score 3, 21.2 in score 4, 12.2 in score 5, 17.6 in score 6, 30.0 in score 7 and 114.8 in score 8. ER-EIA values in ER-IHC-score 8 were significantly higher than in scores 0, 2, 3, 4, 5, 6 and 7. Of the 125 patients, 35 (28%) were immunohistologically positive for HER2. HER2 expression was inversely correlated with ER expression. When evaluated even in ER-positive patients, HER2 overexpression was associated with lower ER levels. In this study, we conducted immunohistochemical double staining with ER and HER2, and demonstrated that low ER levels might be one factor in the relative resistance of HER2-positive and ER-positive tumors to hormonal therapy.
对125例浸润性乳腺癌女性患者的组织样本进行了雌激素受体（ER）和表皮生长因子受体2（HER2）免疫组化双重染色。手术时年龄范围为28至82岁。42例患者肿瘤大小为2 cm或更小，83例患者肿瘤大小大于2 cm。53例患者腋窝淋巴结状态为阳性，72例为阴性。采用酶免疫测定法（EIA）检测的雌激素受体（ER），67例患者为阳性，50例为阴性，8例未知。在评估的125例患者中，83例（66.4%）ER免疫组化呈阳性。免疫组化（IHC）检测的ER（ER-IHC）与EIA检测的ER（ER-EIA）显著相关（p<0.01）。ER-IHC评分中ER-EIA值在0分为1.4 fmol/mg蛋白，1分为0.0，3分为19.0，4分为21.2，5分为12.2，6分为17.6，7分为30.0，8分为114.8。ER-IHC评分为8分的ER-EIA值显著高于0、2、3、4、5、6和7分。125例患者中，35例（28%）HER2免疫组化呈阳性。HER2表达与ER表达呈负相关。即使在ER阳性患者中评估，HER2过表达也与较低的ER水平相关。在本研究中，我们进行了ER和HER2免疫组化双重染色，并证明低ER水平可能是HER2阳性和ER阳性肿瘤对激素治疗相对耐药的一个因素。
